Drugs / OCT461201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06398925 | Jul → Sep 2023 | — | Oxford Cannabinoid Technologies Holdings PLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCT461201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06398925 ↗ |
| Route | Oral | “Oral capsule” NCT06398925 ↗ |